Business
NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences
Next-generation engineered probiotic targeting myostatin and Activin-A pathways advances toward clinical readiness across human and animal health applicationsNEWPORT BEACH, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a wholly owned subsidiary of PMGC Holdings Inc. (“PMGC” or the “Company”) (NASDAQ: ELAB), today announced a key development milestone for its asset, EL-32: the successful transfer of the EL-32 Working Cell Bank (“WCB”) to a U.
About this update from Pmgc Holdings Inc.
[{"type":"image","alt":"PMGC Holdings Inc.","displaySize":"","headline":null,"caption":"PMGC Holdings Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":243,"url":"https://media.zenfs.com/en/globenewswire.com/546741842ddd656c130df2366fbdd9a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3h0SJSUB0Ahuse6N.VnWfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM0MA--/https://media.zenfs.com/en/globenewswire.com/546741842ddd656c130df2366fbdd9a7","width":300,"height":243}},"lazy":false},{"type":"text","content":"Next-generation engineered probiotic targeting myostatin and Activin-A pathways advances toward clinical readiness across human and animal health applications","length":158,"tagName":"p"},{"type":"text","content":"NEWPORT BEACH, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a wholly owned subsidiary of PMGC Holdings Inc. (“PMGC” or the “Company”) (NASDAQ: ELAB), today announced a key development milestone for its asset, EL-32: the successful transfer of the EL-32 Working Cell Bank (“WCB”) to a U.S.-based third-party fermentation facility. This transfer initiates a manufacturing optimization program designed to increase production yield and establish a cost-efficient, scalable process in support of future clinical and commercial development.","length":591,"tagName":"p"},{"type":"text","content":"EL-32 is a dual-action engineered probiotic therapeutic designed to express both myostatin and activin-A antigens, two key biological regulators of muscle development and metabolic function. By targeting both the myostatin and activin-A pathways through an oral, gut-mediated delivery mechanism, EL-32 offers a differentiated approach to preserving lean muscle mass and addressing metabolic dysfunction in patients undergoing GLP-1 receptor agonist weight loss therapy.","length":469,"tagName":"p"},{"type":"text","content":"Modulant Biosciences LLC (“Modulant Biosciences”), licensee for the development, manufacture, and commercialization of products derived from EL-32 for non-human animal health applications under the previously announced License Agreement with NorthStrive Biosciences, has retained the third-party precision fermentation facility to lead upstream and downstream process development. This involves applying data-driven optimization strategies to improve yield, consis...